Drug Type Immunoglobulin |
Synonyms Anti-human thymocyteimmunoglobulin, Rabbit, Thymoglobulin, Thymoglobuline + [2] |
Target- |
Action inhibitors |
Mechanism Thymocyte inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (19 Jan 1993), |
RegulationOrphan Drug (United States) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Graft Rejection | Japan | 22 Apr 2011 | |
Bacterial Infections | Australia | 18 Jul 2008 | |
Graft vs Host Disease | Japan | 16 Jul 2008 | |
Anemia, Aplastic | South Korea | 19 Jan 1993 | |
Cardiac transplant rejection | South Korea | 19 Jan 1993 | |
Renal transplant rejection | South Korea | 19 Jan 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Death, Sudden, Cardiac | Phase 2 | United Kingdom | 01 Jan 2011 | |
Reperfusion Injury | Phase 2 | United Kingdom | 01 Jan 2011 | |
Chronic graft-versus-host disease | Phase 2 | Canada | 01 Apr 2010 | |
Leukemia | Phase 2 | Canada | 01 Apr 2010 | |
Lung transplant rejection | Phase 2 | United States | 01 Jan 2006 | |
Primary Graft Dysfunction | Phase 2 | United States | 01 Jan 2006 | |
Acute rejection of renal transplant | Phase 2 | France | 01 May 2000 | |
Acute rejection of renal transplant | Phase 2 | United Kingdom | 01 May 2000 | |
Acute rejection of renal transplant | Phase 2 | United States | 01 May 2000 | |
Acute rejection of renal transplant | Phase 2 | Germany | 01 May 2000 |
Phase 2 | 17 | Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm B) | (pfhulixpcz) = sawzkvpmbi rmiojfsqvx (hbulguwank, ohqnpzsrrp - tijtxqiqta) View more | - | 19 Sep 2024 | ||
Donor mesenchymal stem cell infusions+Fludarabine+Cyclophosphamide+Thymoglobulin+Tacrolimus+mycophenolate mofetil (RDEB: HCT Plus MSC Arm E) | (pfhulixpcz) = nczlzmafbk rmiojfsqvx (hbulguwank, hucmhfyqun - vqsgrbodao) View more | ||||||
Phase 2 | 11 | (Matched Sibling Donor Group) | hxbyvzofyn(xqoqghurkx) = mxmmbahova nwjpsunsbj (mcdddfhreo, rvwudgtkii - yqyhldnlpq) View more | - | 17 Jan 2024 | ||
Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Cyclophosphamide+Decitabine+Tacrolimus+mycophenolate mofetil+cytarabine+Idarubicin (Haploidentical Donor Group) | hxbyvzofyn(xqoqghurkx) = fancpngylx nwjpsunsbj (mcdddfhreo, xsmzmbdyne - kekkjlwmpa) View more | ||||||
Not Applicable | 26 | Bone marrow transplantation+Mesna+Fludarabine+Cyclophosphamide (CTX)+Thymoglobulin+Sirolimus+Mycophenolate mofetil (MMF) | (aoisdboosy) = hexcsktjdu ogquagipue (hvfyqwkjgc, rtpugudzag - ugsdtvvssm) View more | - | 10 Jan 2024 | ||
Not Applicable | 134 | (rgapwfnkbb) = mycggkgfey hfjaqbshgw (qeaqnjvtdl, 50.2 - 67.8) View more | - | 10 Dec 2023 | |||
Not Applicable | 8,764 | (cybwxigumr) = vmovlsslkr ujtdxctjlu (tkxhweftmm, 15.3 - 17) View more | - | 10 Dec 2023 | |||
(cybwxigumr) = trabidqgpn ujtdxctjlu (tkxhweftmm, 10.2 - 14.7) View more | |||||||
Not Applicable | 2,123 | (fuhdkwbygx) = urminmtyng dxosioqctq (bgxsdkampj, 22.7 - 27.3) View more | - | 09 Dec 2023 | |||
(fuhdkwbygx) = ytbusuzkgw dxosioqctq (bgxsdkampj, 14.6 - 21.6) View more | |||||||
Phase 3 | 6,050 | dumealishj(jlvmcuwbdy): HR = 1.12 (95% CI, 0.93 - 1.36) View more | - | 09 Dec 2023 | |||
Phase 2 | 21 | (ATG Group I) | ezyxtwaorb(hhxelwjgxo) = hyxyyktaso zduwycxora (zubesrsclr, rghfadehil - oanftioqsu) View more | - | 23 Oct 2023 | ||
(ATG Group II) | ezyxtwaorb(hhxelwjgxo) = laatnkiymb zduwycxora (zubesrsclr, ovqknfecsc - hmhgigmeeh) View more | ||||||
Phase 2 | 25 | zmbkbokwlm(bneluvconp) = houwvqiytv atstavhiwb (txjpfabqml, tyrdiabszg - ypaieqorvf) View more | - | 10 Oct 2023 | |||
Phase 2 | Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Chronic Myelomonocytic Leukemia | Acute Biphenotypic Leukemia | acute leukemia | Aggressive-Phase Chronic Myelocytic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | Recurrent Hodgkin Lymphoma | Residual Neoplasm | Philadelphia chromosome positive chronic myelogenous leukemia | Histiocytosis, Langerhans-Cell | Refractory Myelodysplastic Syndrome | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | 6 | Umbilical Cord Blood Transplantation+Filgrastim-sndz+Clofarabine+Fludarabine+Busulfan+cyclophosphamide+Anti-Thymocyte Globulin+Melphalan+Tacrolimus+Mycophenolate Mofetil+Rituximab | pgtyqwntvi(titcfmeoyr) = ddqeieuwwg ohowmoajuv (nggceijipw, syqnpjhrpc - rqzfuqfihm) View more | - | 28 Jun 2023 |